Your browser doesn't support javascript.
loading
The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
Malhotra, Bimal K; Schoenhard, Grant L; de Kater, Annelies W; Friedmann, Nadav.
Afiliação
  • Malhotra BK; Senior Director, Pfizer Inc, New York, New York.
  • Schoenhard GL; Chief Scientific Officer, Pain Therapeutics, Inc., Austin, Texas.
  • de Kater AW; Pain Therapeutics, Inc., Austin, Texas.
  • Friedmann N; Chief Operating and Medical Officer, Pain Therapeutics, Inc., Austin, Texas.
J Opioid Manag ; 11(2): 157-69, 2015.
Article em En | MEDLINE | ID: mdl-25901481

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxicodona / Dor / Insuficiência Renal / Hepatopatias Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxicodona / Dor / Insuficiência Renal / Hepatopatias Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article